Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	591	540	907	2,126	3,541	3,167
Market Cap Growth	5.89%	-40.45%	-57.34%	-39.95%	11.80%	-3.19%
Enterprise Value	196	81	379	1,659	2,703	2,632
PE Ratio	-	-1.65	-2.66	-11.68	-11.19	-17.16
PS Ratio	9090.13	5685.98	5814.63	18.64	-	-
PB Ratio	1.28	1.06	1.36	2.30	3.28	5.04
P/FCF Ratio	-3.32	-2.26	-4.02	-10.31	-19.56	-16.83
P/OCF Ratio	-3.33	-2.27	-4.11	-11.51	-30.76	-23.06
EV/Sales Ratio	3010.87	854.52	2432.50	14.54	-	-
EV/EBITDA Ratio	-1.29	-0.26	-1.16	-9.67	-8.75	-14.58
EV/EBIT Ratio	-1.23	-0.25	-1.11	-9.11	-8.54	-14.23
EV/FCF Ratio	-1.59	-0.34	-1.68	-8.04	-14.93	-13.99
Quick Ratio	12.79	12.38	9.82	9.76	8.88	16.17
Current Ratio	12.80	12.38	9.84	9.84	8.96	16.46
Asset Turnover	0	0	0	0.10	0	0
Return on Equity (ROE)	-53.90%	-56.70%	-44.40%	-18.30%	-31.90%	-28.60%
Return on Assets (ROA)	-43.30%	-45.60%	-37.60%	-16.40%	-28.80%	-25.50%
Return on Capital (ROIC)	-64.63%	-63.98%	-50.31%	-19.48%	-23.92%	-32.11%
Earnings Yield	-49.68%	-60.59%	-37.53%	-8.56%	-8.94%	-5.83%
FCF Yield	-38.50%	-44.29%	-24.88%	-9.70%	-5.11%	-5.94%
Buyback Yield / Dilution	-16.99%	-9.63%	-5.39%	-12.84%	-19.11%	-249.11%
Total Shareholder Return	-16.99%	-9.63%	-5.39%	-12.84%	-19.11%	-249.11%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).